Drug Trial Radar · NCT06542731
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jun 1, 2021
Primary completion
Oct 30, 2025
Study completion Oct 30, 2025
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug
Conditions
- Non-small Cell Lung Cancer
Interventions
ONO-4578Drug
Specified dose on specified days
ONO-4538Drug
Specified dose on specified days
DocetaxelDrug
Specified dose on specified days
RamucirumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities(DLT)Time frame: 21 days
- Adverse event(AE)Time frame: Up to 28 days after the last dose
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Juntendo University Hospital
Bunkyō City, Japan
Japan Anti-Tuberculosis Association Fukujuji Hospital
Kiyose-shi, Japan
The Cancer Institute Hospital of JFCR
Kōtoku, Japan
Niigata Cancer Center Hospital
Niigata, Japan
Hyogo Medical University Hospital
Nishinomiya-shi, Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute
Osaka, Japan
Kitasato University Hospital
Sagamihara-shi, Japan
National Hospital Organization Kinki-Chuo Chest Medical Center
Sakai, Japan
Teikyo University Hospital
tabashi City, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki-shi, Japan
Kanagawa Cancer Center
Yokohama, Japan
Saitama Cancer Center
Shinden, Saitama, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.